Guardant Health (GH) Reaches New 1-Year High on Strong Earnings
Guardant Health Inc (NASDAQ:GH) shares hit a new 52-week high during mid-day trading on Tuesday after the company announced better than expected quarterly earnings. The company traded as high as $74.82 and last traded at $74.00, with a volume of 973532 shares traded. The stock had previously closed at $66.82.
The company reported ($0.30) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.05. The firm had revenue of $32.87 million for the quarter, compared to the consensus estimate of $24.57 million.
Several brokerages recently commented on GH. JPMorgan Chase & Co. upped their target price on Guardant Health from $42.00 to $85.00 and gave the company an “overweight” rating in a report on Wednesday. William Blair reiterated an “outperform” rating on shares of Guardant Health in a report on Wednesday. Finally, Bank of America reiterated a “neutral” rating and issued a $60.00 target price (up from $42.00) on shares of Guardant Health in a report on Thursday, February 28th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $72.50.
Institutional investors have recently bought and sold shares of the business. Jennison Associates LLC bought a new position in shares of Guardant Health during the 4th quarter worth approximately $31,700,000. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $26,000. TD Asset Management Inc. acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $765,000. Kornitzer Capital Management Inc. KS acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $2,096,000. Finally, Brandywine Managers LLC acquired a new position in shares of Guardant Health during the fourth quarter worth approximately $267,000. Hedge funds and other institutional investors own 69.54% of the company’s stock.
The stock has a market capitalization of $6.35 billion and a price-to-earnings ratio of -34.83.
Guardant Health Company Profile (NASDAQ:GH)
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
Featured Story: What is the downside to momentum investing?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.